依西美坦在预防环境中的应用。
Exemestane in the prevention setting.
机构信息
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA.
出版信息
Ther Adv Med Oncol. 2012 May;4(3):107-12. doi: 10.1177/1758834012438214.
Abstract
Aromatase inhibitors are well-established therapies in the neoadjuvant, adjuvant and metastatic settings for breast cancer. In adjuvant trials, this class of drugs has shown preventative properties by decreasing the rate of contralateral breast cancer. Recently, the National Cancer Institute of Canada Clinical Trials Group MAP.3 study evaluated exemestane as a breast cancer prevention agent for women with specified higher risks of developing breast cancer. We review the history of exemestane and evaluate the available evidence of its use for breast cancer prevention.
摘要
芳香酶抑制剂是乳腺癌新辅助治疗、辅助治疗和转移性治疗的成熟疗法。在辅助试验中，该类药物通过降低对侧乳腺癌的发生率显示出预防作用。最近，加拿大国家癌症研究所临床试验组 MAP.3 研究评估了依西美坦作为特定高乳腺癌风险女性的乳腺癌预防药物。我们回顾了依西美坦的历史，并评估了其用于乳腺癌预防的现有证据。
相似文献
1
Exemestane in the prevention setting.依西美坦在预防环境中的应用。
Ther Adv Med Oncol. 2012 May;4(3):107-12. doi: 10.1177/1758834012438214.
2
Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.芳香化酶抑制剂用于辅助性及预防性乳腺癌内分泌治疗的试验
Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):900s-5s.
3
Aromatase inhibitors and breast cancer prevention.芳香酶抑制剂与乳腺癌预防。
Expert Opin Pharmacother. 2012 Feb;13(3):325-31. doi: 10.1517/14656566.2012.651459. Epub 2012 Jan 14.
4
Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.所有芳香化酶抑制剂都一样吗？乳腺癌对照临床试验综述。
Clin Ther. 2005 Nov;27(11):1671-84. doi: 10.1016/j.clinthera.2005.11.013.
5
Prevention strategies with aromatase inhibitors.
Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):372S-9S. doi: 10.1158/1078-0432.ccr-031210.
6
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.降低绝经后女性他莫昔芬治疗结束后乳腺癌复发风险。
Clin Ther. 2007 Aug;29(8):1535-47. doi: 10.1016/j.clinthera.2007.08.013.
7
Anti-aromatase agents in the treatment and prevention of breast cancer.抗芳香化酶药物在乳腺癌治疗与预防中的应用
Cancer Control. 2002 Mar-Apr;9(2 Suppl):2-8. doi: 10.1177/107327480200902S01.
8
The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial.加拿大国家癌症研究所临床试验组 MAP.3 试验：一项国际乳腺癌预防试验。
Curr Oncol. 2007 Jun;14(3):89-96. doi: 10.3747/co.2007.117.
9
Exemestane: a review of its clinical efficacy and safety.依西美坦：临床疗效与安全性综述
Breast. 2001 Jun;10(3):198-208. doi: 10.1054/brst.2001.0293.
10
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.在接受依西美坦进行乳腺癌初级预防的健康绝经后妇女中，骨密度和结构：MAP.3 随机对照试验的嵌套子研究。
Lancet Oncol. 2012 Mar;13(3):275-84. doi: 10.1016/S1470-2045(11)70389-8. Epub 2012 Feb 7.
引用本文的文献
1
Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence.依维莫司联合依西美坦治疗激素受体阳性晚期乳腺癌的疗效和安全性：一项前瞻性、随机、对照、多中心临床研究
Adv Ther. 2022 Feb;39(2):862-891. doi: 10.1007/s12325-021-01924-2. Epub 2022 Jan 6.
2
Validation of a rapid and sensitive LC-MS/MS method for determination of exemestane and its metabolites, 17β-hydroxyexemestane and 17β-hydroxyexemestane-17-O-β-D-glucuronide: application to human pharmacokinetics study.一种用于测定依西美坦及其代谢物17β-羟基依西美坦和17β-羟基依西美坦-17-O-β-D-葡萄糖醛酸苷的快速灵敏的液相色谱-串联质谱法的验证：应用于人体药代动力学研究
PLoS One. 2015 Mar 20;10(3):e0118553. doi: 10.1371/journal.pone.0118553. eCollection 2015.
3
Cancer prevention as biomodulation: targeting the initiating stimulus and secondary adaptations.癌症预防的生物调节：针对引发刺激和次级适应。
Ann N Y Acad Sci. 2012 Oct;1271(1):1-9. doi: 10.1111/j.1749-6632.2012.06736.x.
本文引用的文献
1
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies.绝经后妇女循环性激素与乳腺癌危险因素： 13 项研究的重新分析。
Br J Cancer. 2011 Aug 23;105(5):709-22. doi: 10.1038/bjc.2011.254. Epub 2011 Jul 19.
2
Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.一项新辅助治疗的 II 期临床试验：在绝经后妇女的乳腺癌中联合应用依西美坦与塞来昔布。
Clin Breast Cancer. 2011 Aug;11(4):221-7. doi: 10.1016/j.clbc.2011.03.022. Epub 2011 May 19.
3
Exemestane for breast-cancer prevention in postmenopausal women.依西美坦用于绝经后妇女的乳腺癌预防。
N Engl J Med. 2011 Jun 23;364(25):2381-91. doi: 10.1056/NEJMoa1103507. Epub 2011 Jun 4.
4
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.随机Ⅱ期新辅助对比来曲唑、阿那曲唑和依西美坦治疗绝经后雌激素受体阳性 2-3 期乳腺癌患者：临床和生物标志物结果以及基于 PAM50 的基线内在亚型的预测价值——ACOSOG Z1031。
J Clin Oncol. 2011 Jun 10;29(17):2342-9. doi: 10.1200/JCO.2010.31.6950. Epub 2011 May 9.
5
Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study.绝经后乳腺癌患者在接受内分泌治疗前后的自我报告认知功能：来自神经心理 TEAM 辅助研究的结果。
Psychooncology. 2012 May;21(5):479-87. doi: 10.1002/pon.1928. Epub 2011 Feb 23.
6
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.早期乳腺癌中辅助他莫昔芬和依西美坦（TEAM）的研究：一项随机 3 期试验。
Lancet. 2011 Jan 22;377(9762):321-31. doi: 10.1016/S0140-6736(10)62312-4.
7
The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies.依西美坦与他莫昔芬对 Tamoxifen Exemestane Adjuvant Multinational（TEAM）试验中骨健康的影响：美国、德国、荷兰和比利时亚研究的荟萃分析。
J Cancer Res Clin Oncol. 2011 Jun;137(6):1015-25. doi: 10.1007/s00432-010-0964-y. Epub 2010 Dec 18.
8
A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer.甾体和非甾体芳香化酶抑制剂在转移性乳腺癌中无交叉耐药性的证据基础的定性系统评价。
Clin Oncol (R Coll Radiol). 2011 Apr;23(3):209-15. doi: 10.1016/j.clon.2010.11.005. Epub 2010 Dec 4.
9
Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis.患者对乳腺癌化学预防的决策：系统评价和荟萃分析。
J Clin Oncol. 2010 Jun 20;28(18):3090-5. doi: 10.1200/JCO.2009.27.8077. Epub 2010 May 10.
10
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.国家外科辅助乳腺和肠道项目（National Surgical Adjuvant Breast and Bowel Project）他莫昔芬和雷洛昔芬（Tamoxifen and Raloxifene）试验（STAR）P-2 研究更新：预防乳腺癌。
Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.
Zotero 插件